secwatch.observer — SEC 8-K summary
======================================

Issuer:     Telomir Pharmaceuticals, Inc. (TELO)
CIK:        0001971532
Form:       8-K
Filed at:   2025-07-23T23:59:59+00:00
Accession:  0001641172-25-020687
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Telomir Pharmaceuticals reports Telomir-1 restores mitochondrial function without cell division in Progeria study
--------------------------------------------------------------------------------

- Telomir-1 increased mitochondrial energy (WST-1 assay) and reduced ROS under basal and stress conditions.
- No increase in live cell number was observed, confirming no stimulation of cell proliferation.
- Activity was greater in Progeria fibroblasts than in healthy cells, suggesting disease-selective effects.
- Results may inform development in Parkinson's, ALS, Alzheimer's, Werner's, and Progeria.
- IND-enabling studies for Telomir-1 are ongoing; clinical path evaluation continues.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1971532/000164117225020687/0001641172-25-020687-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1971532/000164117225020687/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-020687

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer